ZA200409676B - Novel drug compositions based on novel anticholinergics and inhibitors of EGFR-kinase - Google Patents

Novel drug compositions based on novel anticholinergics and inhibitors of EGFR-kinase

Info

Publication number
ZA200409676B
ZA200409676B ZA200409676A ZA200409676A ZA200409676B ZA 200409676 B ZA200409676 B ZA 200409676B ZA 200409676 A ZA200409676 A ZA 200409676A ZA 200409676 A ZA200409676 A ZA 200409676A ZA 200409676 B ZA200409676 B ZA 200409676B
Authority
ZA
South Africa
Prior art keywords
novel
kinase inhibitor
egfr
anticholinergic agent
medicament
Prior art date
Application number
ZA200409676A
Inventor
Michel Pairet
Christopher J M Meade
Michael P Pieper
Birgit Jung
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ZA200409676B publication Critical patent/ZA200409676B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A medicament (A) comprises a combination of 6beta ,7beta -epoxy-3beta -hydroxy-8-methyl-1alpha H,5alpha -H-tropanium salt 2,2-diphenylpropionate ester anticholinergic agent(s) (I) and EFGR kinase inhibitor(s) (II), optionally together with auxiliaries. A medicament (A) comprises a combination of tropane derivative anticholinergic agent(s) of formula (I) and EGFR kinase inhibitor(s) (II) (optionally in the form of enantiomers, enantiomer mixtures or racemates, or solvates or hydrates), optionally together with pharmaceutical auxiliaries. [Image] X ->monovalent anion, preferably chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulfonate. An independent claim is also included for new anticholinergic agent(s) of formula (I). ACTIVITY : Antiinflammatory; Antiasthmatic; Antiallergic; Hypotensive. No biological data available. MECHANISM OF ACTION : Anticholinergic; EFGR kinase inhibitor.
ZA200409676A 2002-07-09 2004-11-30 Novel drug compositions based on novel anticholinergics and inhibitors of EGFR-kinase ZA200409676B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10230751A DE10230751A1 (en) 2002-07-09 2002-07-09 New drug compositions based on new anticholinergics and EGFR kinase inhibitors

Publications (1)

Publication Number Publication Date
ZA200409676B true ZA200409676B (en) 2006-05-31

Family

ID=29761746

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200409676A ZA200409676B (en) 2002-07-09 2004-11-30 Novel drug compositions based on novel anticholinergics and inhibitors of EGFR-kinase

Country Status (16)

Country Link
EP (2) EP1521595B1 (en)
JP (1) JP2005537250A (en)
CN (1) CN1665539A (en)
AT (1) ATE320269T1 (en)
AU (1) AU2003242771B2 (en)
BR (1) BR0312507A (en)
CA (1) CA2492037A1 (en)
DE (2) DE10230751A1 (en)
ES (1) ES2259769T3 (en)
MX (1) MXPA05000163A (en)
NZ (1) NZ538096A (en)
PL (1) PL374022A1 (en)
RU (1) RU2317828C2 (en)
TW (1) TW200520757A (en)
WO (1) WO2004004775A1 (en)
ZA (1) ZA200409676B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4194365B2 (en) 2000-10-31 2008-12-10 エムジーアイ ファーマ バイオロジックス インコーポレイテッド CYP1B1 nucleic acids and methods of use
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
SI2422786T1 (en) * 2004-04-22 2014-12-31 Boehringer Ingelheim International Gmbh New medicine combinations for treating respiratory diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
CA2600636A1 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
JP5270343B2 (en) 2005-08-15 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Beta mimetic manufacturing method
DK2402317T3 (en) 2006-03-31 2013-10-07 Novartis Ag DGAT inhibitor
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2927925A (en) * 1960-03-08 Scopine and sgopoline esters of alpha
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
NO166268C (en) 1985-07-30 1991-07-03 Glaxo Group Ltd DEVICE FOR ADMINISTRATING PATIENTS TO PATIENTS.
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IL107120A (en) 1992-09-29 1997-09-30 Boehringer Ingelheim Int Atomising nozzle and filter and spray generating device
DE4318455A1 (en) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Capsule holder
DE19536903C2 (en) 1995-10-04 1998-09-10 Boehringer Ingelheim Int Device for holding a fluidic component
DE19536902A1 (en) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Miniature fluid pressure generating device
DE19545226C1 (en) 1995-12-05 1997-06-19 Boehringer Ingelheim Int Locking mechanism for a spring-operated output
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
UA71976C2 (en) * 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10050994A1 (en) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma New diphenylalkanoic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease
DE10206505A1 (en) * 2002-02-16 2003-08-28 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and EGFR kinase inhibitors
DE10203753A1 (en) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma New xanthene carboxylic acid esters, processes for their preparation and their use as medicines

Also Published As

Publication number Publication date
EP1658860A1 (en) 2006-05-24
MXPA05000163A (en) 2005-04-08
ES2259769T3 (en) 2006-10-16
ATE320269T1 (en) 2006-04-15
CN1665539A (en) 2005-09-07
AU2003242771B2 (en) 2009-07-30
AU2003242771A1 (en) 2004-01-23
TW200520757A (en) 2005-07-01
CA2492037A1 (en) 2004-01-15
NZ538096A (en) 2007-04-27
DE10230751A1 (en) 2004-01-22
RU2005103397A (en) 2006-03-20
PL374022A1 (en) 2005-09-19
EP1521595B1 (en) 2006-03-15
JP2005537250A (en) 2005-12-08
EP1521595A1 (en) 2005-04-13
RU2317828C2 (en) 2008-02-27
WO2004004775A1 (en) 2004-01-15
DE50302675D1 (en) 2006-05-11
BR0312507A (en) 2005-04-12

Similar Documents

Publication Publication Date Title
CO5540380A2 (en) INHALATIVE MEDICINES CONTAINING A NEW ANTI-POLINERGIC IN COMBINATION WITH CORTICOSTEROIDS AND BETAMIMETICS
ECSP055600A (en) Aerosol formulation for inhalation, containing an anticholinergic agent
NO2013002I2 (en) Aclidinium salt with a pharmaceutically acceptable anion of a mono- or polyhydric acid, especially aclidinium bromide
RS51585B (en) Aerosol formulation for inhalation, containing an anticholinergic agent
RS50269B (en) NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND β-MIMETICS
JP2003504368A5 (en)
ZA200409676B (en) Novel drug compositions based on novel anticholinergics and inhibitors of EGFR-kinase
SE0202430D0 (en) New Compounds
NO964871L (en) New agonist compounds
AR039404A1 (en) COMBINATIONS OF MEDICINES CONTAINING HETEROCICLICAL COMPOUNDS AND AN ANTI-POLINERGIC AGENT. AEROSOL FOR YOUR INHALATION
AR039275A1 (en) MEDICINAL CONTAINING STEROIDS AND A NEW ANTI-POLINERGY
AU2003222290A1 (en) Novel ester hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, methods for the production thereof, and use thereof as a medicament
AU2003208703A1 (en) Difurylglycolic acid tropenol esters used as anticholinesterase drugs
TH65935A (en) Drugs, which contain steroids And the new anticolinergic
RU99113936A (en) 1,4-DIAZABICYCLO DERIVATIVES [2.2.2.] OCT-2-ylmethylbenzoate, their production and therapeutic use